Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis—A Pilot Study

Preclinical studies show that blocking Interleukin–1 (IL–1) retards the progression of Amyotrophic Lateral Sclerosis (ALS). We assessed the safety of Anakinra (ANA), an IL–1 receptor antagonist, in ALS patients. In a single arm pilot study we treated 17 ALS patients with ANA (100 mg) daily for one y...

Descripción completa

Detalles Bibliográficos
Autores principales: Maier, André, Deigendesch, Nikolaus, Müller, Kathrin, Weishaupt, Jochen H., Krannich, Alexander, Röhle, Robert, Meissner, Felix, Molawi, Kaaweh, Münch, Christoph, Holm, Teresa, Meyer, Robert, Meyer, Thomas, Zychlinsky, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596620/
https://www.ncbi.nlm.nih.gov/pubmed/26444282
http://dx.doi.org/10.1371/journal.pone.0139684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596620/
https://www.ncbi.nlm.nih.gov/pubmed/26444282
http://dx.doi.org/10.1371/journal.pone.0139684

Ejemplares similares